Inicure AB
559493-9430ActiveDeveloping novel small molecules to combat resistant bacterial infections effectively.
Oversikt
- 0
- Ansatte
- ≤1t SEK
- Omsetning
- 2024
- Grunnlagt
Nøkkelbeslutningstakere
Peter Olofsson-Sahl
CEO
Johan Bylund
CSO
Sara Malcus
Chair Board of Directors
Felix Sanchez Klose
Researcher — Product Development
Beskrivelse
Inicure AB is a biotechnology company spun off from Pronoxis AB, established in 2024. The core mission of the organization is to combat the growing global threat of antibiotic resistance. They specialize in developing novel anti-infectious assets based on activating the formyl peptide receptor-1 (FP...
Tagger
Nøkkelord
Teknologier i bruk
Bedriftsinformasjon
- Bransje
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE559493943001
Beslutningstakere
4 kontakter i FunnelfeedrPeter Olofsson-Sahl
CEO
Johan Bylund
CSO
Sara Malcus
Chair Board of Directors
Andre kontakter
Felix Sanchez Klose
Researcher — Product Development
Lignende bedrifter
20 lignende bedrifter i FunnelfeedrQureTech Bio AB
5–9 ansatteDeveloping novel synthetic antibiotics to combat drug-resistant bacteria.
Ribocure Pharmaceuticals AB
20–49 ansatteClinical stage biotech developing cutting-edge RNA therapeutics for rare diseases.
Linnane Pharma AB
Developing novel drugs for cancer and infections via proprietary platform.
ProNoxis AB
1 ansatteDeveloping small molecule drugs targeting NOX2 activation for inflammation treatment.
SynAct Pharma AB
5–9 ansatteClinical-stage biotech resolving inflammation via novel oral therapies.
Utforsk mer
Spørsmål om Inicure AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo